Theragnostics inks AstraZeneca agreement

AuntMinnie.com staff writers
Sep 4, 2019

Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.

The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.
Latest in Radiation Oncology/Therapy
Prostate Imaging
PSMA PET-guided radiotherapy shows promise
October 3, 2025
Accuray
Accuray partners with UW-Madison
October 1, 2025
Astro Sf
ASTRO: Short prostate SBRT reduces side effects, but not PSA levels
October 1, 2025
Img 2757
ASTRO: STAR has role in managing VT in cardiac patients
October 1, 2025
Related Stories
2021 09 14 23 49 7847 Business Handshake 400
Molecular Imaging
Theragnostics enters licensing deal with AAA for Ga-68 PET
2020 07 28 23 23 5650 Business Hands Cooperation 400
Molecular Imaging
Theragnostics names two new board directors
2017 09 14 23 05 1167 Cancer Cell 400
Molecular Imaging
Theragnostics, German hospital to study THG-008 for PET
2018 08 28 18 59 9066 Artificial Intelligence Ai 400
AI
AstraZeneca, Qure.ai partner for lung cancer diagnosis
More in Radiation Oncology/Therapy
PSMA PET-guided radiotherapy shows promise
By Will Morton
A trial demonstrated that radiotherapy informed by PSMA-PET led to improved outcomes in prostate cancer patients.
October 3, 2025
Prostate Imaging
Accuray partners with UW-Madison
By AuntMinnie.com staff writers
The first helical radiation delivery platform, the TomoTherapy system, was invented by UW-Madison researchers.
October 1, 2025
Accuray
ASTRO: Short prostate SBRT reduces side effects, but not PSA levels
By Kate Madden Yee
Study findings offer new evidence to help guide treatment decisions for patients with localized prostate cancer, researchers said.
October 1, 2025
Astro Sf
ASTRO: STAR has role in managing VT in cardiac patients
By Amerigo Allegretto
Stereotactic arrhythmia radiotherapy (STAR) is safe and effective for treating refractory VT compared to repeat catheter ablation.
October 1, 2025
Img 2757
ASTRO: Daily MRgRT recontouring improves prostate treatment outcomes
By Kate Madden Yee
Daily online adaptive recontouring is associated with clinically meaningful benefit in patient-reported quality of life measures.
September 30, 2025
Astro Sf
ASTRO: Radiation therapy comparable to surgery for early-stage lung cancer
By Will Morton
At 10 years, overall survival was virtually identical between patients treated with radiation therapy versus surgery.
September 30, 2025
Moscone Center
ASTRO: Proton therapy shows promise in breast cancer treatment
By Amerigo Allegretto
Proton radiation achieves similar health-related quality of life measures compared to photon radiation in breast cancer patients.
September 30, 2025
Img 2757
ASTRO: Trial suggests postoperative RT in high-risk bladder cancer
By Liz Carey
Moderate doses of radiation therapy (RT) after bladder removal surgery cut rates of new pelvic cancer, according to researchers.
September 30, 2025
Moscone Center Astro
ASTRO: Lu-177 PNT2002 added to SBRT delays prostate cancer progression
By Will Morton
Two cycles of lutetium-177 PNT2002 before stereotactic body radiation therapy (SBRT) significantly improved progression-free survival.
September 29, 2025
Moscone Center Astro
ASTRO: Contemporary IMRT comparable to proton therapy for throat cancer
By Liz Carey
Phase III U.K. TORPEdO trial investigated proton beam therapy for reducing long-term treatment-related toxicities.
September 29, 2025
Moscone Center Astro
ASTRO: Low-dose RT effective for treating knee osteoarthritis
By Amerigo Allegretto
Research presented at ASTRO 2025 showed the effectiveness of low-dose radiation therapy for treating knee osteoarthritis.
September 29, 2025
Moscone Center Astro
ASTRO: Genomic test predicts benefit of hormone therapy in prostate cancer
By Will Morton
Patients with a prostate tumor subtype known as luminal B had meaningful benefits from the addition of apalutamide to secondary radiotherapy.
September 29, 2025
Moscone Center Astro
Page 1 of 466
Next Page